Movement Alert｜Revolution Medicines Falls 5.11% in Pre-Market Trading, Trading at $172.36

Market Focus

Jul 17

On July 17, Revolution Medicines fell 5.11% in pre-market trading, trading at $172.36 USD/share, with Turnover of $44,900.

Within the Biotechnology sector where Revolution Medicines belongs, the overall sector showed modest gains. Among individual stocks, AbbVie up 0.88%, Amgen up 0.84%, Gilead Sciences up 0.72%, Regeneron Pharmaceuticals up 0.72%, Vertex Pharmaceuticals up 0.41%.

Revolution Medicines is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit RAS-addicted cancers. Its core pipeline candidate daraxonrasib previously demonstrated significant overall survival benefit in a Phase 3 trial for metastatic pancreatic cancer and has entered EMA phased review and FDA filing preparation, while the company is actively building a global self-commercialization team.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1189616395"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1189616395\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1189616395?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-17 16:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1189616395","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Revolution Medicines Falls 5.11% in Pre-Market Trading, Trading at $172.36","media":"Market Focus","content":"<p><p>On July 17, Revolution Medicines fell 5.11% in pre-market trading, trading at $172.36 USD/share, with Turnover of $44,900.</p><p>Within the Biotechnology sector where Revolution Medicines belongs, the overall sector showed modest gains. Among individual stocks, AbbVie up 0.88%, Amgen up 0.84%, Gilead Sciences up 0.72%, Regeneron Pharmaceuticals up 0.72%, Vertex Pharmaceuticals up 0.41%.</p><p>Revolution Medicines is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit RAS-addicted cancers. Its core pipeline candidate daraxonrasib previously demonstrated significant overall survival benefit in a Phase 3 trial for metastatic pancreatic cancer and has entered EMA phased review and FDA filing preparation, while the company is actively building a global self-commercialization team.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Revolution Medicines Falls 5.11% in Pre-Market Trading, Trading at $172.36</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Revolution Medicines Falls 5.11% in Pre-Market Trading, Trading at $172.36\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-17 16:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 17, Revolution Medicines fell 5.11% in pre-market trading, trading at $172.36 USD/share, with Turnover of $44,900.</p><p>Within the Biotechnology sector where Revolution Medicines belongs, the overall sector showed modest gains. Among individual stocks, AbbVie up 0.88%, Amgen up 0.84%, Gilead Sciences up 0.72%, Regeneron Pharmaceuticals up 0.72%, Vertex Pharmaceuticals up 0.41%.</p><p>Revolution Medicines is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit RAS-addicted cancers. Its core pipeline candidate daraxonrasib previously demonstrated significant overall survival benefit in a Phase 3 trial for metastatic pancreatic cancer and has entered EMA phased review and FDA filing preparation, while the company is actively building a global self-commercialization team.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RVMD","symbol_name":"Revolution Medicines, Inc.","start_time":0,"source_url":"","article_id":"1189616395","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1189616395","pubTimestamp":1784277217,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 17, Revolution Medicines fell 5.11% in pre-market trading, trading at $172.36 USD/share, with Turnover of $44,900.Within the Biotechnology sector where Revolution Medicines belongs, the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RVMD":"Revolution Medicines, Inc."},"translate_title":"走势警报|Revolution Medicines 盘前交易下跌 5.11%，交易价格为 172.36 美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RVMD":1},"content_text":"On July 17, Revolution Medicines fell 5.11% in pre-market trading, trading at $172.36 USD/share, with Turnover of $44,900.Within the Biotechnology sector where Revolution Medicines belongs, the overall sector showed modest gains. Among individual stocks, AbbVie up 0.88%, Amgen up 0.84%, Gilead Sciences up 0.72%, Regeneron Pharmaceuticals up 0.72%, Vertex Pharmaceuticals up 0.41%.Revolution Medicines is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit RAS-addicted cancers. Its core pipeline candidate daraxonrasib previously demonstrated significant overall survival benefit in a Phase 3 trial for metastatic pancreatic cancer and has entered EMA phased review and FDA filing preparation, while the company is actively building a global self-commercialization team.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}